|
US2015184154A1
|
|
New treatment for neurodegenerative diseases
|
|
US2015218238A1
|
|
Treating diseases by modulating a specific isoform of mkl1
|
|
WO2013072392A1
|
|
Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway
|
|
WO2013068431A1
|
|
New treatment for neurodegenerative diseases
|
|
WO2013068413A1
|
|
Rod cell-specific promoter
|
|
EP2776838A1
|
|
Early diagnostic of neurodegenerative diseases
|
|
WO2012168259A1
|
|
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
|
EP2699669A1
|
|
Culture medium suitable for the culture of undifferentiated cells
|
|
WO2012065937A1
|
|
Anti-fungal agents
|
|
WO2012032143A1
|
|
Phosphorylated twist1 and metastasis
|
|
EP2580239A1
|
|
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
|
US2013034543A1
|
|
Modulating xrn1
|
|
EP2552451A1
|
|
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells
|
|
EP2542578A1
|
|
Smoc1, tenascin-c and brain cancers
|
|
EP2493492A1
|
|
Phosphorylated twist1 and cancer
|
|
WO2011045352A2
|
|
Spleen tyrosine kinase and brain cancers
|
|
EP2483394A1
|
|
Functionalized organotypic systems
|
|
TN2010000442A1
|
|
Antiviral therapy
|
|
EP2480573A1
|
|
Treating cancer by modulating mex-3
|
|
EP2470557A1
|
|
Genetic vasectomy by overexpression of prml-egfp fusion protein in spermatids
|
